PDCD1 and neoplasm: The anti-tumor effect was evaluated for CGA, anti-PD-1 antibody and their combination; the results showed that combination of CGA with anti-PD-1 antibody had a better therapeutic effect than monotherapy, causing additional suppression on tumor growth in either “Hot” or “Altered” xenograft models (31.1% therapeutic effect increasing for MC38, p < 0.05; 24.5% therapeutic effect increasing for 4T1, p < 0.01).